Jakob-Creutzfeldt disease

Jakob-Creutzfeldt disease (JCD), more commonly known as Creutzfeldt-Jakob disease (CJD), is a rare, degenerative, invariably fatal brain disorder. It affects about one in every one million people per year worldwide; in the United States, there are about 350 cases per year. CJD usually appears in later life and runs a rapid course. Typically, onset of symptoms occurs at about age 60, and death follows within one year.

Symptoms

The initial symptoms of CJD are characterized by rapidly progressive neurological deterioration, leading to memory loss, personality changes, and hallucinations. Physical symptoms include sudden movements, muscle stiffness, and weakness. As the disease progresses, mental impairment becomes severe. Individuals may experience blindness, insomnia, incoordination, and coma. The symptoms of CJD are caused by the destruction of brain cells, but the exact mechanism is not fully understood.

Causes

CJD is caused by an abnormal infectious protein called a prion. Prions are misfolded proteins that replicate by converting their properly folded counterparts into the disease-associated form. This process leads to brain damage and the characteristic signs and symptoms of the disease. CJD can occur sporadically, be inherited, or be transmitted by exposure to brain or nervous system tissue, usually through certain medical procedures. There are three main types of CJD: sporadic (the most common form), hereditary, and acquired.

Diagnosis

Diagnosis of CJD can be challenging, especially in the early stages of the disease. It is often based on the combination of clinical symptoms, neurological examination, and a series of diagnostic tests. These tests may include MRI scans of the brain, which can show characteristic patterns associated with CJD, and analysis of cerebrospinal fluid obtained via lumbar puncture for the presence of specific proteins. In some cases, a brain biopsy may be performed to confirm the diagnosis, although this is less common due to the risks involved.

Treatment

There is currently no cure for CJD. Treatment is aimed at relieving symptoms and making the individual as comfortable as possible. This may include medications to control pain, seizures, or agitation, and interventions to help with feeding and breathing as the disease progresses.

Prevention

Preventing CJD involves reducing the risk of exposure to the infectious prions. This includes implementing strict controls on medical equipment and procedures to avoid contamination with infected brain or nervous system tissue. For hereditary CJD, genetic counseling may be offered to family members.

Epidemiology

CJD is a rare disease worldwide. The sporadic form occurs at a rate of about one case per million people per year. Hereditary CJD accounts for 10-15% of all cases, while acquired CJD is even less common.

History

The disease was first described in the 1920s by German neurologists Hans Gerhard Creutzfeldt and Alfons Maria Jakob, who independently reported cases of an unusual neurological disorder. It was later recognized that these cases were manifestations of the same disease, which was named after them.

‎